Business Context and Reporting Period
This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2016, filed November 9, 2016. The filing identifies the registrant as Aeglea BioTherapeutics, Inc., not Spyre Therapeutics, Inc.; investors should verify the entity and filing metadata.
Aeglea was an early-stage biotechnology company developing engineered enzyme-based therapeutics for amino-acid metabolism. Its lead candidate, AEB1102, was in Phase 1 development for advanced solid tumors, acute myeloid leukemia/myelodysplastic syndrome, and Arginase I deficiency. The company had no product revenue and generated revenue solely from a CPRIT research grant.
Key Financial Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Grant revenue | $1.1 million in 2016 versus $1.1 million in 2015 | $3.4 million versus $4.5 million |
| Research and development expense | $5.4 million versus $3.1 million | $13.4 million versus $7.5 million |
| General and administrative expense | $2.1 million versus $1.4 million | $6.3 million versus $4.3 million |
| Net loss | $6.2 million versus $3.4 million | $16.2 million versus $7.3 million |
| Net loss per share | $0.47 versus $5.57 | $1.89 versus $12.76 |
| Net cash used in operating activities | $14.5 million in 2016 versus $10.1 million in 2015 |
Operating margins were not meaningful because revenue consisted only of grant reimbursements and was substantially below operating expenses. Nine-month operating loss was $16.4 million, compared with $7.3 million in the prior-year period. Stock-based compensation was $1.0 million for the first nine months of 2016.
At September 30, 2016, cash and cash equivalents were $49.5 million, marketable securities were $18.5 million, and total cash, cash equivalents and marketable securities were $68.0 million. Working capital was $67.8 million, accumulated deficit was $39.8 million, and total liabilities were $3.9 million. The company reported no debt facility or outstanding debt.
Material Changes Versus the Prior Comparable Period
- Third-quarter R&D expense increased 72% and nine-month R&D expense increased 79%, primarily because of higher toxicology, personnel, clinical development, manufacturing and intellectual-property costs related to AEB1102.
- G&A expense increased 52% in the quarter and 46% year to date, reflecting additional personnel, professional fees, insurance and public-company costs.
- Nine-month grant revenue declined 25% because the 2015 period included recognition of accumulated qualifying expenditures upon execution of the CPRIT grant contract.
- The company completed its April 2016 IPO, selling 5.5 million shares for $54.8 million of gross proceeds and $47.3 million of net proceeds. Outstanding preferred stock converted into 7.2 million common shares.
- Cash increased by $20.3 million during the first nine months, primarily because IPO financing more than offset operating cash burn and purchases of marketable securities.
Guidance, Outlook, Risks and Unusual Items
Management expected continued and increasing losses as clinical trials, manufacturing, nonclinical research, pipeline development, intellectual-property activities and public-company costs expanded. Management stated that existing cash, cash equivalents and marketable securities were expected to fund operations and capital requirements through at least June 30, 2018, while also acknowledging that additional financing would eventually be required and that the estimate could prove incorrect.
- AEB1102 Phase 1 trials were ongoing in three indications. Enrollment in the Arginase I deficiency trial was expected to be completed in 2016, with topline data expected in the first half of 2017; enrollment in the hematological malignancy trial was expected to be completed in 2017.
- The CPRIT grant could provide up to $19.8 million through May 31, 2017. Approximately $11.7 million remained available for future collection at September 30, 2016, subject to qualifying expenditures and grant conditions. Future commercial products based on grant-funded intellectual property could require tiered royalties to CPRIT.
- University license agreements could require up to $6.4 million in milestone payments per licensed product, plus annual fees and low-single-digit royalties on net sales.
- Future minimum office lease payments totaled approximately $1.2 million through 2020. The University research agreement was extended through August 2017 with a $750,000 increase in its expenditure limit.
- Principal risks included clinical-trial failure or delay, patient-enrollment constraints in rare diseases, adverse events, regulatory approval uncertainty, reliance on third-party manufacturers and clinical organizations, intellectual-property challenges, competition, dependence on additional financing and potential shareholder dilution.
- The company disclosed serious adverse events, including deaths, in some oncology trial patients, although investigators had not assessed those events as related to AEB1102 as of the filing.
- In October 2016, after the quarter end, the Chief Medical Officer resigned and the company began searching for a replacement.
Investor Verification Items
- Confirm that this filing belongs to Aeglea BioTherapeutics, Inc. and reconcile it with the requested Spyre Therapeutics, Inc. metadata.
- Verify current cash runway against the company’s June 30, 2018 estimate, particularly actual clinical-trial spending and financing activity after September 30, 2016.
- Review subsequent clinical, regulatory and safety results for AEB1102, including the Arginase I deficiency and oncology programs.
- Assess the remaining availability and reimbursement conditions of the CPRIT grant and the related royalty obligations.
- Review potential dilution from equity compensation, future financings and the approximately 7.2 million shares subject to registration rights.
- Evaluate third-party manufacturing, clinical-trial execution and intellectual-property licensing dependencies.